In a report released today, Alex Arfaei from BMO Capital assigned a Hold rating to Eli Lilly & Co (NYSE: LLY). The company’s shares closed yesterday at $90.03, close to its 52-week high of $90.13.
According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 6.0% and a 70.4% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Merck & Company, Bristol Myers, and AstraZeneca.
Eli Lilly & Co has an analyst consensus of Moderate Buy, with a price target consensus of $96.40, a 7.1% upside from current levels. In a report issued on July 13, Credit Suisse also maintained a Hold rating on the stock with a $84 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $90.13 and a one-year low of $73.69. Currently, Eli Lilly & Co has an average volume of 3.63M.
Based on the recent corporate insider activity of 110 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through two segments: Human Pharmaceutical Products and Animal Health.
